Btk
Bruton tyrosine kinase
Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.
Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca2+ stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.
All Product Categories
-
Btk Related Products (271)
Related Products (271)
-
Recombinant Proteins (19)
-
Antibodies (3)
-
SJF620 hydrochloride
0 ImagesCat. No.: HY-133137ACAS No.: 2821938-05-8
-
Dihydrodiol-Ibrutinib-d5
0 ImagesCat. No.: HY-100659SCAS No.: 2068022-09-1Synonyms: PCI-45227-d5Dihydrodiol-Ibrutinib-d5 is the deuterium labeled Dihydrodiol-Ibrutinib (HY-100659). Dihydrodiol-Ibrutinib is a dihydrodiol active metabolite of Ibrutinib (HY-10997), has inhibitory activity towards BTK approximately 15 times lower than that of ibrutinib.
-
(R)-Elsubrutinib
0 ImagesSynonyms: (R)-ABBV-105(R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor. (R)-Elsubrutinib can be used in studies of immune diseases (such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus) and cancer.
-
Acalabrutinib (Standard)
0 ImagesSynonyms: ACP-196 (Standard)Acalabrutinib (Standard) is the analytical standard of Acalabrutinib. This product is intended for research and analytical applications. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
Acalabrutinib maleate
0 ImagesCat. No.: HY-17600ACAS No.: 2242394-65-4Synonyms: Calquence maleate; ACP-196 maleateAcalabrutinib (Calquence) maleate is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib maleate demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib maleate can be used for CLL research. Acalabrutinib maleate is a click chemistry reagent, which contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
BTK inhibitor 13
0 ImagesCat. No.: HY-130255CAS No.: 2376726-26-8BTK inhibitor 13 is an orally active Bruton's tyrosine kinase (BTK) inhibitor, with an IC50 value of 1.2 nM against human BTK. BTK inhibitor 13 covalently modifies the Cys481 residue of BTK when binding to the inactive conformation of BTK. BTK inhibitor 13 is used for the research of autoimmune diseases.
-
Civorebrutinib
0 ImagesCat. No.: HY-111781CAS No.: 2155853-43-1Synonyms: WS-413Civorebrutinib (WS-413) is a selective, orally active BTK and TEC inhibitor with an IC50 of <100 nM for both targets. Civorebrutinib inhibits B cell activation. Civorebrutinib significantly suppresses the in vivo growth of diffuse large B-cell lymphoma cells. Civorebrutinib can be used for the research of diffuse large B-cell lymphoma.
-
BTK-IN-5
0 ImagesCat. No.: HY-115876CAS No.: 2145152-06-1BTK-IN-5 is a covalent BTK inhibitor for researching medical conditions such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes.
-
CFON-026
0 ImagesCat. No.: HY-174850CAS No.: 2941611-57-8CFON-026 is a selective, orally active and non-covalent BTK inhibitor with an IC50 of 0.27 nM. CFON-026 has significant antitumor activity against wild-type BTK (TMD8 and REC-1) and all clinically relevant BTK resistance mutations (BTK C481S, T474I, L528W and V416L). CFON-026 induces complete tumor regression in TMD8 xenograft mice model. CFON-026 can be used for research of hematological cancers like chronic lymphocytic leukemia and waldenström macroglobulinemia.
-
TM471-1
0 ImagesCat. No.: HY-174129CAS No.: 2649008-95-5
-
BMS-986143
0 ImagesCat. No.: HY-145373CAS No.: 1643372-83-1
-
G-744
0 ImagesCat. No.: HY-102036CAS No.: 1346669-54-2
-
Cinsebrutinib
0 ImagesCat. No.: HY-156604CAS No.: 2724962-58-5Cinsebrutinib is a Bruton's tyrosine kinase inhibitor, extracted from patent WO2021207549 (compound 5-6). Cinsebrutinib has the potential for cancer study.
-
CHMFL-BTK-01
0 ImagesCat. No.: HY-101521CAS No.: 2095280-64-9
